UY35854A - Métodos para la conjugación de oxima con polipéptidos ceto-modificados - Google Patents
Métodos para la conjugación de oxima con polipéptidos ceto-modificadosInfo
- Publication number
- UY35854A UY35854A UY0001035854A UY35854A UY35854A UY 35854 A UY35854 A UY 35854A UY 0001035854 A UY0001035854 A UY 0001035854A UY 35854 A UY35854 A UY 35854A UY 35854 A UY35854 A UY 35854A
- Authority
- UY
- Uruguay
- Prior art keywords
- protein
- oxima
- conjugation
- key
- methods
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
- C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
- C07K1/1133—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure by redox-reactions involving cystein/cystin side chains
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/64—Cyclic peptides containing only normal peptide links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Virology (AREA)
- Analytical Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La invención proporciona métodos mejorados para preparar conjugados de proteínas a partir de una proteína ceto-modificada. En una modalidad, la proteína se prepara mediante la unión de dos cisteínas libres por reacción con un 1,3-dihaloacetona o reactivo que contiene cetona similar, que une los átomos de azufre de las dos cisteínas. En otra modalidad, dos residuos de cisteína están unidos por reacción con una 1,3-dihaloacetona o reactivo similar, y la nueva cetona se utiliza para formar una oxima con una molécula de grupo funcional adecuada, c onjugando así la proteína a un grupo funcional.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361909236P | 2013-11-26 | 2013-11-26 | |
US201462002614P | 2014-05-23 | 2014-05-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
UY35854A true UY35854A (es) | 2015-06-30 |
Family
ID=52117931
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY0001035854A UY35854A (es) | 2013-11-26 | 2014-11-25 | Métodos para la conjugación de oxima con polipéptidos ceto-modificados |
Country Status (15)
Country | Link |
---|---|
US (1) | US10172948B2 (es) |
EP (1) | EP3074048B1 (es) |
JP (1) | JP6609563B2 (es) |
KR (1) | KR20160088429A (es) |
CN (1) | CN105764530B (es) |
AU (1) | AU2014356126B2 (es) |
CA (1) | CA2928087A1 (es) |
EA (1) | EA201691075A1 (es) |
ES (1) | ES2729643T3 (es) |
IL (1) | IL245244A0 (es) |
MX (1) | MX2016006674A (es) |
TW (1) | TWI572361B (es) |
UY (1) | UY35854A (es) |
WO (1) | WO2015079376A1 (es) |
ZA (1) | ZA201602603B (es) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EA201591049A1 (ru) | 2012-11-30 | 2015-09-30 | Новартис Аг | Способы получения конъюгатов дисульфидсодержащих белков |
US10588980B2 (en) | 2014-06-23 | 2020-03-17 | Novartis Ag | Fatty acids and their use in conjugation to biomolecules |
WO2016036794A1 (en) | 2014-09-03 | 2016-03-10 | Immunogen, Inc. | Conjugates comprising cell-binding agents and cytotoxic agents |
US20190194315A1 (en) | 2015-06-17 | 2019-06-27 | Novartis Ag | Antibody drug conjugates |
WO2017051254A1 (en) * | 2015-09-25 | 2017-03-30 | Legochem Biosciences, Inc. | Compositions and methods related to anti-egfr antibody drug conjugates |
MA44334A (fr) | 2015-10-29 | 2018-09-05 | Novartis Ag | Conjugués d'anticorps comprenant un agoniste du récepteur de type toll |
EP3380126A4 (en) | 2015-11-25 | 2019-07-24 | LegoChem Biosciences, Inc. | ANTIBODY-MEDICINAL CONJUGATES COMPRISING BRANCHED LINKS AND RELATED METHODS |
CN117244076A (zh) | 2015-11-25 | 2023-12-19 | 乐高化学生物科学股份有限公司 | 包含自降解基团的缀合物及其相关方法 |
JP7002733B2 (ja) * | 2016-11-18 | 2022-02-04 | 国立大学法人 鹿児島大学 | IgG結合ペプチドを含む固相担体及びIgGの分離方法 |
KR101938800B1 (ko) | 2017-03-29 | 2019-04-10 | 주식회사 레고켐 바이오사이언스 | 피롤로벤조디아제핀 이량체 전구체 및 이의 리간드-링커 접합체 화합물 |
AR111651A1 (es) | 2017-04-28 | 2019-08-07 | Novartis Ag | Conjugados de anticuerpos que comprenden agonistas del receptor de tipo toll y terapias de combinación |
TW202000239A (zh) | 2018-05-09 | 2020-01-01 | 韓商樂高化學生物科學股份有限公司 | 與抗cd19抗體藥物結合物相關之組合物及方法 |
KR20210028544A (ko) | 2019-09-04 | 2021-03-12 | 주식회사 레고켐 바이오사이언스 | 인간 ror1에 대한 항체를 포함하는 항체 약물 접합체 및 이의 용도 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6239110B1 (en) | 1990-02-22 | 2001-05-29 | W.R. Grace & Co. -Conn. | Synthetic analogs of thrombospondin and therapeutic use thereof |
WO1999013062A1 (en) | 1997-09-09 | 1999-03-18 | Nycomed Imaging As | Factors vii fragments and analogs thereof and their use in the treatment of blood clotting disorders |
WO1999013063A1 (en) | 1997-09-09 | 1999-03-18 | Nycomed Imaging As | Factor vii fragments and analogs thereof and their use in the treatment of blood clottng disorders |
GB0316294D0 (en) * | 2003-07-11 | 2003-08-13 | Polytherics Ltd | Conjugated biological molecules and their preparation |
US8673848B2 (en) | 2012-01-27 | 2014-03-18 | Novartis Ag | Synthetic apelin mimetics for the treatment of heart failure |
US20090131306A1 (en) | 2007-06-15 | 2009-05-21 | Adherex Technologies, Inc. | Chemically modified cyclic peptides containing cell adhesion recognition (car) sequences and uses therefor |
WO2010025510A1 (en) | 2008-09-03 | 2010-03-11 | Xenome Ltd | Libraries of peptide conjugates and methods for making them |
BR112012003089A2 (pt) | 2009-08-10 | 2016-08-16 | Ucl Business Plc | ligação covalente reversível de moléculas funcionais |
CA2887129A1 (en) | 2012-10-09 | 2014-04-17 | Igenica, Inc. | Anti-c16orf54 antibodies and methods of use thereof |
CA2891261C (en) | 2012-11-15 | 2023-04-04 | Brandeis University | Tethering cysteine residues using cyclic disulfides |
EA201591049A1 (ru) * | 2012-11-30 | 2015-09-30 | Новартис Аг | Способы получения конъюгатов дисульфидсодержащих белков |
-
2014
- 2014-11-24 WO PCT/IB2014/066300 patent/WO2015079376A1/en active Application Filing
- 2014-11-24 EP EP14815051.9A patent/EP3074048B1/en not_active Not-in-force
- 2014-11-24 CA CA2928087A patent/CA2928087A1/en not_active Abandoned
- 2014-11-24 US US14/551,187 patent/US10172948B2/en active Active
- 2014-11-24 CN CN201480064270.7A patent/CN105764530B/zh not_active Expired - Fee Related
- 2014-11-24 AU AU2014356126A patent/AU2014356126B2/en not_active Ceased
- 2014-11-24 ES ES14815051T patent/ES2729643T3/es active Active
- 2014-11-24 MX MX2016006674A patent/MX2016006674A/es unknown
- 2014-11-24 EA EA201691075A patent/EA201691075A1/ru unknown
- 2014-11-24 JP JP2016554939A patent/JP6609563B2/ja not_active Expired - Fee Related
- 2014-11-24 KR KR1020167016645A patent/KR20160088429A/ko not_active Application Discontinuation
- 2014-11-25 TW TW103140861A patent/TWI572361B/zh not_active IP Right Cessation
- 2014-11-25 UY UY0001035854A patent/UY35854A/es not_active Application Discontinuation
-
2016
- 2016-04-15 ZA ZA2016/02603A patent/ZA201602603B/en unknown
- 2016-04-20 IL IL245244A patent/IL245244A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
IL245244A0 (en) | 2016-06-30 |
TW201524520A (zh) | 2015-07-01 |
TWI572361B (zh) | 2017-03-01 |
AU2014356126A1 (en) | 2016-05-19 |
JP6609563B2 (ja) | 2019-11-20 |
AU2014356126B2 (en) | 2017-01-05 |
EP3074048A1 (en) | 2016-10-05 |
EA201691075A1 (ru) | 2016-09-30 |
JP2016539190A (ja) | 2016-12-15 |
KR20160088429A (ko) | 2016-07-25 |
WO2015079376A1 (en) | 2015-06-04 |
CN105764530B (zh) | 2019-09-13 |
US20150150998A1 (en) | 2015-06-04 |
ZA201602603B (en) | 2017-06-28 |
CA2928087A1 (en) | 2015-06-04 |
MX2016006674A (es) | 2016-12-09 |
CN105764530A (zh) | 2016-07-13 |
US10172948B2 (en) | 2019-01-08 |
EP3074048B1 (en) | 2019-03-06 |
ES2729643T3 (es) | 2019-11-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UY35854A (es) | Métodos para la conjugación de oxima con polipéptidos ceto-modificados | |
CO2018005436A2 (es) | Anticuerpos y fragmentos de anticuerpo para la conjugación sitio-específica | |
CO2018013471A2 (es) | Anticuerpos anti-b7-h3 y conjugados de anticuerpo y fármaco | |
BR112017019300A2 (pt) | conjugado de fórmula genérica ama - l - x - s - ab, método para sintetizar um conjugado de fórmula genérica ama - l - x - s - ab, kit, método para sintetizar o composto ama - l - x', composição farmacêutica e método para tratar uma doença associada a células que apresentam um alvo | |
BR112019000970A2 (pt) | proteínas de ligação ao antígeno multiespecíficas e métodos de uso das mesmas | |
BR112018071276A2 (pt) | anticorpos anti-il-33, composições, métodos e usos dos mesmos | |
ECSP18023386A (es) | Moléculas de unión a linfopoyetina estromal timica (tslp) y métodos de uso de las moléculas | |
CO2018002446A2 (es) | Moléculas de unión a linfopoyetina estromal timica (tslp) y métodos de uso de las moléculas | |
DOP2018000281A (es) | Anticuerpos específicos para la tau hiperfosforilada y sus métodos de uso | |
CR20160206A (es) | Composiciones y métodos para anticuerpos que se dirigen a la proteína de complemento C5 | |
EA201491644A1 (ru) | Фармацевтические композиции | |
CL2019001324A1 (es) | Anticuerpos anti-met, moleculas de unión a antígeno bispecificas que se unen a met y métodos de uso de los mismos. | |
CU20170169A7 (es) | Anticuerpos de factor xi | |
CY1121964T1 (el) | Αντισωματα εναντιον toy csf-1r | |
BR112018075653A2 (pt) | anticorpos anti-b7-h3 e conjugados anticorpo fármaco | |
EA201690667A1 (ru) | Композиции, содержащие антитело к pdl1 | |
BR112018002033A2 (pt) | ligantes covalentes em conjugados de anticorpo-fármaco e métodos para fabricação e uso dos mes-mos | |
BR112017022256A2 (pt) | conjugados de anticorpo-droga sítio-específicos | |
BR112018075651A2 (pt) | anticorpos anti-cd98 e conjugados anticorpo fármaco | |
WO2014134561A3 (en) | Quantification of vaccine compositions | |
UA118332C2 (uk) | Білок, що зв'язує антиген cd27l | |
BR112016014913A8 (pt) | anticorpo, ou um fragmento de ligação ao antígeno do mesmo, conjugado, ácido nucléico, vetor, célula hospedeira, composição farmacêutica, método de preparo de uma cadeia leve de um anticorpo ou fragmento de ligação ao antígeno e método de preparo de um conjugado | |
BR112016017764A2 (pt) | anticorpo antidengue de amplo espectro | |
BR112018075630A2 (pt) | anticorpos anti-cd98 e conjugados de fármaco de anticorpo | |
BR112019012796A2 (pt) | proteínas de ligação ao antígeno antineuropilina e métodos de uso das mesmas |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
109 | Application deemed to be withdrawn |
Effective date: 20211230 |